Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

One of the most critical topics to address in health care today is the mental health and well-being of physicians and other ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...